This article is also featured in @JAMAWomenHealth, a curated source of trusted clinical information that advances health care for women worldwide. 📣 JAMA+ Women's Health amplifies the best of the JAMA Network’s rich Women’s Health content, ensuring it is accessible to global audience across the health spectrum. 📪 Learn more and subscribe to the email newsletter: https://ja.ma/4jGRrd7

🔖 This trial is featured in JAMA+ Trials, a platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health. This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: https://ja.ma/4j8Jop4 📫 Learn more and subscribe to the email newsletter: https://ja.ma/4jOy4yD

📊 Research Summary: In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor–negative disease, with more frequent hematologic toxicity than chemotherapy. https://ja.ma/4jx9xy5 #ESMO26 @myESMO

💬 Editorial by Maria Fernanda Mosele, MD, and Fabrice André, MD, PhD: In #BreastCancer with low erythroblastic oncogene B 2 (ERBB2) expression, trastuzumab rezetecan demonstrates clinically meaningful activity and adds to the growing class of ERBB2-directed antibody-drug conjugates. Its place in care remains uncertain because trastuzumab deruxtecan is already approved in a similar setting and no head-to-head comparison is available. https://ja.ma/4i9zCkf #ESMO26 @myESMO